NeoGenomics, Inc. (NASDAQ: NEO) has caught the attention of investors following a recent rating update from Leerink Partners. Analyst Puneet Souda upgraded the stock to “Outperform” on April 29, 2026, setting a price target of $25—a notable upside considering NEO’s recent trading price of $9.02. This rating shift encapsulates both growing confidence in the company’s future trajectory and a potential opportunity for investors willing to engage with a stock currently believed to be undervalued.
Recent Price Action
NeoGenomics shares have experienced notable fluctuations in recent trading sessions, reflecting broader market dynamics and investor sentiment. Closing last week at $9.02, the stock has seen a decline of approximately 5.95% since the start of the week, contributing to a market cap of roughly $220.8 million. The stock’s current price is significantly below its 52-week high of $115.47, a stark contrast to the 52-week low of $25.98, illustrating the volatility that NEO has faced. With a beta of 1.712, the stock exhibits greater risk relative to the broader market, as evidenced by its average volume of approximately 1.92 million shares compared to the current trading volume of around 4.57 million shares.
[chart type=’price’ value=’NEO’]
Historical Performance
Evaluating NeoGenomics’ performance over various time horizons reveals a mixed outlook. Over the past 30 days, shares rallied by 8.68%, and quarterly returns show an impressive increase of 25.77%. However, the annual performance tells a different story, with shares down nearly 9.59% over the last year. This contrast illustrates the challenges NEO has faced in the longer term amidst a fluctuating healthcare market. Weekly volatility stands at 4.82%, while monthly volatility is slightly lower at 4.57%, highlighting the stock’s price sensitivity to market movements.
[chart type=’performance’ value=’NEO’]
Earnings Analysis
The latest earnings report for NEO, dated October 28, 2025, underscored challenges faced by the company. NeoGenomics reported an earnings per share (EPS) of -$1.06, a staggering miss compared to analysts’ expectations of $0.02, resulting in a surprise factor of -5402.05%. This disappointing performance follows a previous quarter when they met estimates with an EPS of $0.03. Such a significant deviation from expected profits raises concerns about the predictability and quality of the company’s earnings and casts doubt on its near-term financial outlook.
[chart type=’income-bar-chart’ value=’NEO’]
Analyst and Consensus View
Despite recent struggles and mixed performance indicators, consensus ratings for NeoGenomics remain largely optimistic. According to Leerink Partners’ recent assessment, all analysts rate the stock favorably, leading to a sweeping “Buy” consensus. The firm currently holds three total ratings, with an average price target of approximately $17.67. The targeted range includes a high of $25—underscoring the confidence behind the recent “Outperform” rating—and a low of $13. These bullish sentiments suggest that analysts believe significant upside potential remains, even against the backdrop of disappointing earnings.
[chart type=’analyst-ratings’ value=’NEO’]
Stock Grading and Fundamental View
NeoGenomics holds a Stocks Telegraph grading score of 56, an indicator that reflects a balance between potential and current market challenges. This score takes into account various financial metrics and market analyses, hinting at reasonable fundamentals amidst present turmoil. While the grading suggests that NeoGenomics shows promise as an investment, it also underscores the necessity for careful consideration of the company’s overarching health and environment—particularly concerning the volatility witnessed in its share price.
[chart type=’st-cards’ value=’NEO’]
Conclusion
For investors considering NeoGenomics, the stock presents an intriguing opportunity coupled with notable risks. The recent “Outperform” rating from Leerink Partners may appeal to growth-oriented investors willing to tolerate volatility, especially given the substantial upside implied by the price target. However, potential investors should remain cautious; the disappointing EPS results may signal deeper-rooted issues that need addressing. This stock may particularly suit investors looking for long-term growth amidst a recovery phase, but vigilance regarding current earnings quality and market conditions is crucial. Monitoring NeoGenomics will be essential as the company navigates its recovery path and works to bolster investor confidence in the coming quarters.